PUMA BIOTECHNOLOGY, INC. Cash And Cash Equivalents At Carrying Value

Quick Answer

PUMA BIOTECHNOLOGY, INC. reported Cash And Cash Equivalents At Carrying Value of $29.64 million for the year ending 2025.

  • PUMA BIOTECHNOLOGY, INC. showed a decrease of -57.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from PUMA BIOTECHNOLOGY, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
  • XBRL data for this metric is available from 2010 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q2 2007: $0.00 | Q4 2009: $2.4 thousand | Q2 2010: $1.8 thousand | Q1 2011: $0.00 | Q2 2011: $1.7 thousand | Q3 2011: $25.5 thousand | Q1 2012: $50.17 million | Q2 2012: $41.00 million | Q3 2012: $33.35 million | Q1 2013: $91.65 million | Q2 2013: $60.90 million | Q3 2013: $51.26 million | Q1 2014: $163.38 million | Q2 2014: $55.36 million | Q3 2014: $28.26 million | Q1 2015: $155.47 million | Q2 2015: $59.84 million | Q3 2015: $23.60 million | Q1 2016: $78.22 million | Q2 2016: $57.84 million | Q3 2016: $52.54 million | Q1 2017: $105.09 million | Q2 2017: $80.82 million | Q3 2017: $79.72 million | Q1 2018: $78.55 million | Q2 2018: $95.91 million | Q3 2018: $68.30 million | Q1 2019: $48.79 million | Q2 2019: $27.16 million | Q3 2019: $58.90 million | Q1 2020: $83.39 million | Q2 2020: $90.90 million | Q3 2020: $90.08 million | Q1 2021: $95.65 million | Q2 2021: $89.85 million | Q3 2021: $63.95 million | Q1 2022: $63.91 million | Q2 2022: $52.76 million | Q3 2022: $77.96 million | Q1 2023: $61.39 million | Q2 2023: $60.01 million | Q3 2023: $81.80 million | Q1 2024: $76.75 million | Q2 2024: $67.15 million | Q3 2024: $67.26 million | Q1 2025: $63.03 million | Q2 2025: $54.66 million | Q3 2025: $53.53 million.
  • Historical annual values: Fiscal year 2025: $29.64 million | Fiscal year 2024: $69.22 million | Fiscal year 2023: $84.59 million | Fiscal year 2022: $76.20 million | Fiscal year 2021: $63.13 million | Fiscal year 2020: $85.29 million | Fiscal year 2019: $60.04 million | Fiscal year 2018: $108.42 million | Fiscal year 2017: $81.70 million | Fiscal year 2016: $194.49 million | Fiscal year 2015: $31.57 million | Fiscal year 2014: $38.54 million | Fiscal year 2013: $43.04 million | Fiscal year 2012: $137.41 million | Fiscal year 2011: $53.38 million | Fiscal year 2010: $0.00 | Fiscal year 2010: $0.00.
  • Data sourced from SEC EDGAR public filings as of August 10, 2026.

Last verified: